Diabetic vascular diseases: molecular mechanisms and therapeutic strategies

Y Li, Y Liu, S Liu, M Gao, W Wang, K Chen… - Signal transduction and …, 2023 - nature.com
Vascular complications of diabetes pose a severe threat to human health. Prevention and
treatment protocols based on a single vascular complication are no longer suitable for the …

Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity …

F Lopez-Jimenez, W Almahmeed… - European journal of …, 2022 - academic.oup.com
The ongoing obesity epidemic represents a global public health crisis that contributes to
poor health outcomes, reduced quality of life, and> 2.8 million deaths each year. Obesity is …

Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review

KG Young, EH McInnes, RJ Massey… - Communications …, 2023 - nature.com
Background A precision medicine approach in type 2 diabetes requires the identification of
clinical and biological features that are reproducibly associated with differences in clinical …

Sodium‐glucose cotransporter 2 inhibitor canagliflozin antagonizes salt‐sensitive hypertension through modifying transient receptor potential channels 3 mediated …

Y Zhao, L Li, Z Lu, Y Hu, H Zhang, F Sun… - Journal of the …, 2022 - Am Heart Assoc
Background Salt‐sensitive hypertension is highly prevalent and associated with cardiorenal
damage. Large clinical trials have demonstrated that SGLT2 (sodium‐glucose cotransporter …

Preclinical modeling of metabolic syndrome to study the pleiotropic effects of novel antidiabetic therapy independent of obesity

JP Mochel, JL Ward, T Blondel, D Kundu… - Scientific Reports, 2024 - nature.com
Cardiovascular-kidney-metabolic health reflects the interactions between metabolic risk
factors, chronic kidney disease, and the cardiovascular system. A growing body of literature …

Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease

GM Chertow, P Vart, N Jongs… - Diabetes, Obesity …, 2022 - Wiley Online Library
Aim To assess the effects of dapagliflozin in patients with chronic kidney disease (CKD) and
albuminuria, with and without type 2 diabetes, stratified by the Quételet (body mass) index …

Diabetes status modifies the association between different measures of obesity and heart failure risk among older adults: a pooled analysis of community-based …

KV Patel, MW Segar, CJ Lavie, N Kondamudi… - Circulation, 2022 - Am Heart Assoc
Background: Obesity and diabetes are associated with a higher risk of heart failure (HF). The
interrelationships between different measures of adiposity—overall obesity, central obesity …

[HTML][HTML] Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors

KG Young, EH McInnes, RJ Massey, AR Kahkohska… - medRxiv, 2023 - ncbi.nlm.nih.gov
Background: A precision medicine approach in type 2 diabetes requires identification of
clinical and biological features that are reproducibly associated with differences in clinical …

Therapeutic repurposing of antidiabetic drugs in diabetes-associated comorbidities

K Pathak, MP Pathak, R Saikia, U Gogoi… - Current Drug …, 2024 - ingentaconnect.com
Background: Diabetic patients suffer from various comorbidities like cardiovascular diseases
(CVDs), cancer, obesity, cognitive impairment, gout, leishmaniasis, etc. Objective: We aimed …

Epidemiology and treatment of acute and chronic heart failure

F Crea - European Heart Journal, 2023 - academic.oup.com
Boer; 1 'The year in cardiovascular medicine 2022: the top 10 papers in arrhythmias'
authored by Harry JGM Crijns, Pier Lambiase, and Prash Sanders; 2 and 'The year in …